This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Sandia Corporation, The University of New Mexico. Active years: 2013.
Company Filing History:
1 out of 1,769 
1 out of 942 
Years Active: 2013
Title: Edward J Bedrick: Innovator in Pediatric Leukemia Research
Introduction
Edward J Bedrick is a notable inventor based in Albuquerque, NM (US). He has made significant contributions to the field of pediatric oncology, particularly in the area of acute lymphoblastic leukemia (ALL). His work focuses on identifying genetic markers that can help in diagnosing and treating high-risk cases of B-precursor ALL.
Latest Patents
Edward J Bedrick holds a patent titled "Identification of novel subgroups of high-risk pediatric precursor B acute lymphoblastic leukemia, outcome correlations and diagnostic and therapeutic methods related to same." This invention relates to the identification of genetic markers in patients with high-risk B-precursor acute lymphoblastic leukemia (B-ALL) and explores their relationship to therapeutic outcomes. The patent also encompasses diagnostic and prognostic methods utilizing these genetic markers, along with kits that provide microchips and/or immunoreagents for analyzing leukemia patients. He has 1 patent to his name.
Career Highlights
Throughout his career, Edward has worked with esteemed organizations such as the University of New Mexico and Sandia Corporation. His roles in these institutions have allowed him to contribute to groundbreaking research and advancements in medical science.
Collaborations
Edward has collaborated with notable professionals in his field, including Cheryl L Willman and Richard Harvey. Their collective efforts have furthered the understanding and treatment of pediatric leukemia.
Conclusion
Edward J Bedrick's innovative work in identifying genetic markers for high-risk pediatric leukemia has the potential to transform diagnostic and therapeutic approaches in oncology. His contributions are invaluable to the medical community and continue to pave the way for future advancements in cancer treatment.